This Week in Allergy & Immunology — Jul 31, 2026

Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning upper airway interventions and prediction models, diagnostic stewardship in allergy clinics, and the efficacy of both novel and traditional pharmacotherapies. Let's dive in.

We begin with a series of studies addressing chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease, or AERD. For patients with uncontrolled nasal polyps, endoscopic sinus surgery is often necessary, but the optimal extent of surgery remains debated. In a randomized controlled trial published in the journal Allergy, researchers compared full functional endoscopic sinus surgery against a limited surgical approach in ninety-seven patients [4]. The trial, conducted across two university hospitals, randomized patients who had severe disease at baseline, defined by a Sino-nasal-outcome-test score of thirty or greater, a bilateral nasal polyp score of four or greater, and a modified Lund-Mackay radiological score of fourteen or greater. All patients had undergone previous surgery or received systemic medications. The per-protocol analysis included forty-seven patients in the full surgical group and forty-seven in the limited surgical group. At the twelve-month follow-up, patients in the full surgery group had a mean SNOT-22 score of 22.3, compared to 31.5 in the limited surgery group, representing a mean difference of 9.2. However, by twenty-four months, this difference narrowed to 2.5, with scores of 25.3 and 27.8 respectively. Ultimately, the difference in the change of total SNOT-22 scores between the two groups was not statistically significant and did not meet the minimal clinically important difference, although full surgery did show better improvement in secondary outcomes like olfaction and polyp load, suggesting better inflammatory control [4]. Even after successful surgery, recurrence remains a major challenge, especially in patients with eosinophilic nasal polyps. A multicenter cohort study published in the Annals of Allergy, Asthma, & Immunology evaluated twelve hundred and thirty-six patients with eosinophilic polyps to identify predictors of postoperative recurrence [6]. The investigators discovered that comorbid asthma, a serum total immunoglobulin E level greater than 100 international units per milliliter, and a predicted forced expiratory volume in one second of eighty percent or less were independent predictors of recurrence. Interestingly, blood eosinophil count and percentage did not predict recurrence. When these three independent risk factors were combined into a composite score, high-risk patients had a recurrence rate of nearly fifty-seven percent, compared to less than twenty-four percent in the low-risk group, with recurrence rising steeply within the first two months after surgery [6]. For patients who do experience severe, refractory type two inflammation of the unified airway, such as those with AERD, a systematic review and meta-analysis in The Journal of Allergy and Clinical Immunology: In Practice offers strong therapeutic guidance [5]. Synthesizing data from fifteen randomized controlled trials comprising over eight hundred patients with AERD, researchers found that biologics led to significant, clinically meaningful improvements in both upper and lower airway outcomes. Specifically, biologic therapy reduced nasal polyp scores and nasal congestion, improved SNOT-22 scores by an average of nineteen points, improved smell identification scores, and enhanced asthma control and lung function, with all improvements exceeding established minimal clinically important differences [5].

Moving from the upper airway to clinical diagnostics, the British Society for Allergy and Clinical Immunology has published a clinical practice statement in Clinical and Experimental Allergy regarding hospital-based food challenges [1]. While double-blind, placebo-controlled challenges remain the gold standard, the statement highlights that open food challenges are practical, effective tools for daily clinical practice when history and allergy tests are discordant, or when resolution of an allergy is suspected. In the practice statement, the authors recommend that challenge foods be age-specific and delivered in an appropriate form—whether uncooked, cooked, baked, or as a composite food. The protocol must involve giving incrementally increasing amounts of the food until an age-specific top or cumulative dose is consumed. Importantly, the decision to pause or stop a challenge should not rely solely on rigid international guidance; it must integrate clinician judgment, the patient's individual symptom history, and their personal preferences. To maximize safety and positive impact, the authors emphasize that these challenges must be overseen by experienced staff in clinical areas with immediate access to emergency support and a clear pathway for inpatient admission [1]. This clinical statement highlights the need for rigorous diagnostic protocols, which is further supported by a prospective study in the International Archives of Allergy and Immunology [10]. This study evaluated two hundred and eighteen patients presenting to allergy clinics with cutaneous complaints they believed were allergic. In reality, these patients had non-allergic dermatologic conditions. Over eighty percent of patients presented with pruritus, and more than sixty percent had already visited a dermatology clinic. The most common final diagnoses were xerosis cutis, which affected over a quarter of the patients, followed by insect bite reactions, prurigo simplex, seborrheic dermatitis, acne vulgaris, and rosacea. These findings underscore the importance of improved triage and interdisciplinary collaboration to prevent unnecessary allergy workups [10]. Additionally, we saw a publication in the Annals of Allergy, Asthma, & Immunology regarding direct penicillin challenges in the intensive care unit facilitated by electronic consultation, although we will focus our discussion on the clinical trials with complete data [7].

In the realm of pharmacotherapy, a major systematic review and network meta-analysis published in the BMJ challenges a very common clinical practice: the routine use of oral antihistamines for atopic dermatitis [2]. Analyzing forty-seven randomized trials involving over six thousand children and adults with moderate-to-severe eczema, the researchers found that while adding a first- or second-generation H1 antihistamine resulted in a statistically detectable reduction in disease severity and itch, the actual clinical effect was tiny and fell well below the minimal important differences. Furthermore, antihistamines did not improve sleep disturbance or reduce eczema exacerbations. First-generation agents significantly increased cognitive impairment and treatment discontinuation due to adverse events, while the risk of cognitive impairment among second-generation agents varied, ranging from zero cases per thousand for loratadine to seventeen per thousand for cetirizine. The authors conclude that these findings provide strong evidence against the routine use of antihistamines in eczema management [2]. For patients suffering from allergic rhinoconjunctivitis, a double-blind, randomized, placebo-controlled trial published in Allergy evaluated a novel approach: intralymphatic immunotherapy, or ILIT, using a grass pollen allergoid formulated with microcrystalline tyrosine [3]. Sixty adults received three ultrasound-guided injections into their inguinal lymph nodes at four-week intervals. The active group received a dose equivalent to sixty nanograms of the Phl p five allergen, while the control group received a matching placebo. The treatment was well tolerated, with no severe adverse events or systemic allergic reactions. Compared to placebo, the immunotherapy reduced combined symptom and medication scores by thirty-three percent in the first year, which was not statistically significant, but led to a statistically significant fifty percent reduction in the second year, demonstrating promising long-term efficacy and safety [3]. When treating acute asthma exacerbations, predicting which patients will respond to therapy is crucial. A study in Clinical and Experimental Allergy investigated inflammatory mediators associated with corticosteroid responsiveness during asthma attacks [8]. The researchers found that higher baseline sputum or serum levels of eotaxin-three, as well as higher serum interleukin-five levels, were significantly associated with greater improvements in forced expiratory volume in one second following oral corticosteroid treatment, suggesting that corticosteroid-induced inflammatory modulation varies significantly across different type two inflammatory phenotypes [8].

Finally, we turn to environmental exposures and their long-term impact on respiratory health. A narrative review published in The Journal of Allergy and Clinical Immunology examines the relationship between electronic cigarette use, or vaping, and asthma across the lifespan [9]. Despite being marketed as smoking cessation tools, electronic cigarettes are now used by approximately ten percent of middle- and high-school students in the United States. The review synthesizes experimental and epidemiologic evidence linking vaping to the pathogenesis of asthma, chronic obstructive pulmonary disease, and other respiratory disorders, emphasizing an urgent clinical need for healthcare providers to screen for and prevent electronic cigarette use in both youth and adult asthma patients [9].

If you only have time for one paper this week, make it the systematic review and network meta-analysis on antihistamines for atopic dermatitis published in the BMJ [2]. This landmark study provides high-quality, definitive evidence that oral antihistamines offer no clinically meaningful benefit for eczema severity, itching, or sleep, while exposing patients to unnecessary side effects and cognitive impairment, making it a true practice-changing publication that should reshape our daily prescribing habits.

Here are the key takeaways from this week in Allergy & Immunology: First, routine use of oral antihistamines as an add-on therapy for atopic dermatitis does not provide clinically meaningful relief for itch, severity, or sleep, and first-generation agents carry a substantial risk of cognitive impairment. Second, in patients undergoing endoscopic sinus surgery for eosinophilic nasal polyps, comorbid asthma, serum total immunoglobulin E levels above 100 international units per milliliter, and a predicted forced expiratory volume in one second of eighty percent or less are strong, independent predictors of postoperative recurrence. Third, biologic therapies in patients with aspirin-exacerbated respiratory disease deliver substantial, clinically meaningful improvements across both upper and lower airway outcomes, far exceeding minimal clinically important differences. Fourth, intralymphatic immunotherapy using a grass pollen allergoid and microcrystalline tyrosine is safe and achieves a significant, fifty percent reduction in combined symptom and medication scores by the second year of treatment. And fifth, over a quarter of patients presenting to allergy clinics with self-perceived allergic skin conditions actually have xerosis cutis, highlighting the critical need for dermatologic triage and collaborative care.

That's your roundup for This Week in Allergy & Immunology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.